The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

Extracellular acidity enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis via DR5 in gastric cancer cells

  • Hong, Ran (Department of Pathology, College of Medicine, Chosun University) ;
  • Han, Song Iy (Division of Premedical Science, College of Medicine, Chosun University)
  • Received : 2018.02.05
  • Accepted : 2018.05.28
  • Published : 2018.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

The tumor microenvironment greatly influences cancer cell characteristics, and acidic extracellular pH has been implicated as an essential factor in tumor malignancy and the induction of drug resistance. Here, we examined the characteristics of gastric carcinoma (GC) cells under conditions of extracellular acidity and attempted to identify a means of enhancing treatment efficacy. Acidic conditions caused several changes in GC cells adversely affecting chemotherapeutic treatment. Extracellular acidity did inhibit GC cell growth by inducing cell cycle arrest, but did not induce cell death at pH values down to 6.2, which was consistent with down-regulated cyclin D1 and up-regulated p21 mRNA expression. Additionally, an acidic environment altered the expression of atg5, HSPA1B, collagen XIII, collagen XXAI, slug, snail, and zeb1 genes which are related to regulation of cell resistance to cytotoxicity and malignancy, and as expected, resulted in increased resistance of cells to multiple chemotherapeutic drugs including etoposide, doxorubicin, daunorubicin, cisplatin, oxaliplatin and 5-FU. Interestingly, however, acidic environment dramatically sensitized GC cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Consistently, the acidity at pH 6.5 increased mRNA levels of DR4 and DR5 genes, and also elevated protein expression of both death receptors as detected by immunoblotting. Gene silencing analysis showed that of these two receptors, the major role in this effect was played by DR5. Therefore, these results suggest that extracellular acidity can sensitize TRAIL-mediated apoptosis at least partially via DR5 in GCs while it confers resistance to various type of chemotherapeutic drugs.

Keywords

References

  1. Poole-Wilson PA. Measurement of myocardial intracellular pH in pathological states. J Mol Cell Cardiol. 1978;10:511-526. https://doi.org/10.1016/0022-2828(78)90010-X
  2. Reichert M, Steinbach JP, Supra P, Weller M. Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis. Cancer. 2002;95:1113-1119. https://doi.org/10.1002/cncr.10767
  3. Thews O, Gassner B, Kelleher DK, Schwerdt G, Gekle M. Impact of hypoxic and acidic extracellular conditions on cytotoxicity of chemotherapeutic drugs. Adv Exp Med Biol. 2007;599:155-161.
  4. Wilting RH, Dannenberg JH. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat. 2012;15:21-38. https://doi.org/10.1016/j.drup.2012.01.008
  5. Raghunand N, Gillies RJ. pH and drug resistance in tumors. Drug Resist Updat. 2000;3:39-47. https://doi.org/10.1054/drup.2000.0119
  6. Fais S, De Milito A, You H, Qin W. Targeting vacuolar $H^{2+}$-ATPases as a new strategy against cancer. Cancer Res. 2007;67:10627-10630. https://doi.org/10.1158/0008-5472.CAN-07-1805
  7. Taylor S, Spugnini EP, Assaraf YG, Azzarito T, Rauch C, Fais S. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resist Updat. 2015;23:69-78. https://doi.org/10.1016/j.drup.2015.08.004
  8. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, Malvezzi M, La Vecchia C. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009;125:666-673. https://doi.org/10.1002/ijc.24290
  9. Peleteiro B, Severo M, La Vecchia C, Lunet N. Model-based patterns in stomach cancer mortality worldwide. Eur J Cancer Prev. 2014;23:524-531. https://doi.org/10.1097/CEJ.0b013e328364f2b6
  10. Deng K, Lin S, Zhou L, Li Y, Chen M, Wang Y, Li Y. High levels of aromatic amino acids in gastric juice during the early stages of gastric cancer progression. PLoS One. 2012;7:e49434. https://doi.org/10.1371/journal.pone.0049434
  11. Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A, Bailey K, Balagurunathan Y, Rothberg JM, Sloane BF, Johnson J, Gatenby RA, Gillies RJ. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013;73:1524-1535. https://doi.org/10.1158/0008-5472.CAN-12-2796
  12. Wang S. The promise of cancer therapeutics targeting the TNFrelated apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene. 2008;27:6207-6215. https://doi.org/10.1038/onc.2008.298
  13. Gura T. How TRAIL kills cancer cells, but not normal cells. Science. 1997;277:768. https://doi.org/10.1126/science.277.5327.768
  14. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157-163. https://doi.org/10.1038/5517
  15. Kashii Y, Giorda R, Herberman RB, Whiteside TL, Vujanovic NL. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol. 1999;163:5358-5366.
  16. Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene. 1998;17:3261-3270. https://doi.org/10.1038/sj.onc.1202568
  17. Shin JN, Park SY, Cha JH, Park JY, Lee BR, Jung SA, Lee ST, Yun CW, Seol DW, Kim TH. Generation of a novel proform of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein that can be reactivated by matrix metalloproteinases. Exp Cell Res. 2006;312:3892-3898. https://doi.org/10.1016/j.yexcr.2006.08.015
  18. Lim SC, Choi JE, Kang HS, Han SI. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int J Cancer. 2010;126:1582-1595.
  19. Luo S, Rubinsztein DC. Atg5 and Bcl-2 provide novel insights into the interplay between apoptosis and autophagy. Cell Death Differ. 2007;14:1247-1250. https://doi.org/10.1038/sj.cdd.4402149
  20. Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res. 2008;68:1485-1494. https://doi.org/10.1158/0008-5472.CAN-07-0562
  21. Han W, Sun J, Feng L, Wang K, Li D, Pan Q, Chen Y, Jin W, Wang X, Pan H, Jin H. Autophagy inhibition enhances daunorubicininduced apoptosis in K562 cells. PLoS One. 2011;6:e28491. https://doi.org/10.1371/journal.pone.0028491
  22. Buzzard KA, Giaccia AJ, Killender M, Anderson RL. Heat shock protein 72 modulates pathways of stress-induced apoptosis. J Biol Chem. 1998;273:17147-17153. https://doi.org/10.1074/jbc.273.27.17147
  23. Su C, Su B, Tang L, Zhao Y, Zhou C. Effects of collagen iv on cisplatin-induced apoptosis of non-small cell lung cancer cells. Cancer Invest. 2007;25:542-549. https://doi.org/10.1080/07357900701513272
  24. Januchowski R, Swierczewska M, Sterzynska K, Wojtowicz K, Nowicki M, Zabel M. Increased expression of several collagen genes is associated with drug resistance in ovarian cancer cell lines. J Cancer. 2016;7:1295-1310. https://doi.org/10.7150/jca.15371
  25. Vukovic V, Tannock IF. Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br J Cancer. 1997;75:1167-1172. https://doi.org/10.1038/bjc.1997.201
  26. Wachsberger PR, Landry J, Storck C, Davis K, O'Hara MD, Owen CS, Leeper DB, Coss RA. Mammalian cells adapted to growth at pH 6.7 have elevated HSP27 levels and are resistant to cisplatin. Int J Hyperthermia. 1997;13:251-255; discussion 257-9. https://doi.org/10.3109/02656739709023533
  27. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snailinduced EMT of cancer cells. Cancer Cell. 2009;15:195-206. https://doi.org/10.1016/j.ccr.2009.01.023
  28. Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM. The epithelialto-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest. 2018;128:1267-1282. https://doi.org/10.1172/JCI97225
  29. Hardy J, Jones A, Gore ME, Viner C, Selby P, Wiltshaw E. Treatment of advanced ovarian cancer with intraperitoneal tumour necrosis factor. Eur J Cancer. 1990;26:771. https://doi.org/10.1016/0277-5379(90)90146-K
  30. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME. CD95 ligand induces motility and invasiveness of apoptosisresistant tumor cells. EMBO J. 2004;23:3175-3185. https://doi.org/10.1038/sj.emboj.7600325
  31. Srivastava RK. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia. 2001;3:535-546. https://doi.org/10.1038/sj.neo.7900203
  32. Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ. 2014;21:1350-1364. https://doi.org/10.1038/cdd.2014.81
  33. Lim SC, Parajuli KR, Han SI. The alkyllysophospholipid edelfosine enhances TRAIL-mediated apoptosis in gastric cancer cells through death receptor 5 and the mitochondrial pathway. Tumour Biol. 2016;37:6205-6216. https://doi.org/10.1007/s13277-015-4485-9
  34. Jin CY, Park C, Cheong J, Choi BT, Lee TH, Lee JD, Lee WH, Kim GY, Ryu CH, Choi YH. Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. Cancer Lett. 2007;257:56-64. https://doi.org/10.1016/j.canlet.2007.06.019
  35. Jung EM, Park JW, Choi KS, Park JW, Lee HI, Lee KS, Kwon TK. Curcumin sensitizes tumor necrosis factor-related apoptosisinducing ligand (TRAIL)-mediated apoptosis through CHOPindependent DR5 upregulation. Carcinogenesis. 2006;27:2008-2017. https://doi.org/10.1093/carcin/bgl026
  36. Yoon MJ, Kang YJ, Kim IY, Kim EH, Lee JA, Lim JH, Kwon TK, Choi KS. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation. Carcinogenesis. 2013;34:1918-1928. https://doi.org/10.1093/carcin/bgt137
  37. Huang Y, Yang X, Xu T, Kong Q, Zhang Y, Shen Y, Wei Y, Wang G, Chang KJ. Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs. Int J Oncol. 2016;49:153-163. https://doi.org/10.3892/ijo.2016.3525
  38. Lee YJ, Song JJ, Kim JH, Kim HR, Song YK. Low extracellular pH augments TRAIL-induced apoptotic death through the mitochondria-mediated caspase signal transduction pathway. Exp Cell Res. 2004;293:129-143. https://doi.org/10.1016/j.yexcr.2003.09.015

Cited by

  1. Nuclear Lipid Microdomains Regulate Daunorubicin Resistance in Hepatoma Cells vol.19, pp.11, 2018, https://doi.org/10.3390/ijms19113424
  2. Phenotypic transition of tumor cells between epithelial- and mesenchymal-like state during adaptation to acidosis vol.18, pp.16, 2018, https://doi.org/10.1080/15384101.2019.1635868
  3. Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy vol.10, pp.None, 2018, https://doi.org/10.3389/fimmu.2019.01530
  4. Alteration and dysfunction of ion channels/transporters in a hypoxic microenvironment results in the development and progression of gastric cancer vol.44, pp.4, 2018, https://doi.org/10.1007/s13402-021-00604-1